0000950170-23-029861.txt : 20230626 0000950170-23-029861.hdr.sgml : 20230626 20230626160751 ACCESSION NUMBER: 0000950170-23-029861 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230623 FILED AS OF DATE: 20230626 DATE AS OF CHANGE: 20230626 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Reinhart Harald CENTRAL INDEX KEY: 0001835824 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38205 FILM NUMBER: 231042425 MAIL ADDRESS: STREET 1: 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR STREET 2: PUDONG CITY: SHANGHAI STATE: F4 ZIP: 201210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zai Lab Ltd CENTRAL INDEX KEY: 0001704292 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4560 JINKE ROAD STREET 2: BLDG. 1, 4F, PUDONG CITY: SHANGHAI STATE: F4 ZIP: 201210 BUSINESS PHONE: 862161632588 MAIL ADDRESS: STREET 1: 4560 JINKE ROAD STREET 2: BLDG. 1, 4F, PUDONG CITY: SHANGHAI STATE: F4 ZIP: 201210 4 1 ownership.xml 4 X0407 4 2023-06-23 0001704292 Zai Lab Ltd ZLAB 0001835824 Reinhart Harald C/O ZAI LAB LIMITED 314 MAIN STREET, 4TH FLOOR, SUITE 100 CAMBRIDGE MA 02142 false true false false See Remarks false American Depositary Shares 2023-06-23 4 M false 18250 25.30 A 40497 D American Depositary Shares 2023-06-23 4 F false 7182 25.30 D 33315 D Restricted Share Units 0.00 2023-06-23 4 M false 18250 0.00 D American Depositary Shares 18250 54750 D Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs. ADSs acquired on vesting of Restricted Share Units. Each ADS represents ten Ordinary Shares of the issuer. This transaction represents the disposition of shares to cover taxes. Each Restricted Share Unit represents a contingent right to receive one ADS, which represents ten Ordinary Shares of the issuer. The Restricted Share Units vest in equal annual installments over four years beginning on 06/25/2023, the first anniversary of the date of grant. Vested shares will be delivered in the form of ADSs to the reporting person following vesting. President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases /s/ Bruce Blefeld, Attorney-in-Fact 2023-06-26